{"id":"doptelet-pill","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Thromboembolic events"}]},"_chembl":{"chemblId":"CHEMBL2103883","moleculeType":"Small molecule","molecularWeight":"649.67"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Avatrombopag activates the thrombopoietin (TPO) signaling pathway, which promotes megakaryocyte proliferation and maturation, leading to increased platelet production. This mechanism helps restore platelet counts in patients with thrombocytopenia by enhancing endogenous thrombopoiesis without requiring exogenous TPO administration.","oneSentence":"Doptelet (avatrombopag) is a thrombopoietin receptor agonist that stimulates platelet production by binding to the TPO receptor on bone marrow megakaryocytes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:35:24.743Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thrombocytopenia in patients with chronic liver disease undergoing scheduled invasive procedures"},{"name":"Immune thrombocytopenia (ITP)"}]},"trialDetails":[{"nctId":"NCT04845659","phase":"PHASE4","title":"Avatrombopaq In Patients With Cirrhosis","status":"UNKNOWN","sponsor":"Hvidovre University Hospital","startDate":"2021-06-01","conditions":"Thrombocytopenia; Drugs, Cirrhosis, Liver, Procedural Bleeding","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Doptelet Pill","genericName":"Doptelet Pill","companyName":"Hvidovre University Hospital","companyId":"hvidovre-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Doptelet (avatrombopag) is a thrombopoietin receptor agonist that stimulates platelet production by binding to the TPO receptor on bone marrow megakaryocytes. Used for Thrombocytopenia in patients with chronic liver disease undergoing scheduled invasive procedures, Immune thrombocytopenia (ITP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}